Smoking Cessation Label Changes Could Lay Groundwork For Indications
This article was originally published in The Tan Sheet
Executive Summary
FDA drops its requirement for labeling provisions for NRTs on duration of use and concomitant use of tobacco or other NRTs. Meanwhile, the agency rejects citizen petition requests for additional NRT indications, but says it is open to working with sponsors on developing those indications.
You may also be interested in...
Wider Options In FDA's NRT Clinical Trial Guidance, Approval Path Still Narrow
FDA's NRT clinical draft guidance is latest piece of its evolving strategy for making available more products to help smokers quit. But FDA maintains requirements that keep approval bar high and its separate draft guidance published in 2018 on nonclinical trials put NRT progress on hold, says Saul Shiffman, an OTC switch consultant with work includes multiple NRT proposals.
Nicofi Targets Selling E-Cigarette Users And Smokers On A Substitute
Ross Myles Health is not making a smoking cessation or NRT claim for Nicofi sublingual tablets made with steam-extracted pure nicotine, keeping the product free of drug regulation by FDA. While Nicofi also is outside the agency’s current tobacco product authority, the firm is prepared for FDA oversight.
Nicofi Targets Selling E-Cigarette Users And Smokers On A Substitute
Ross Myles Health is not making a smoking cessation or NRT claim for Nicofi sublingual tablets made with steam-extracted pure nicotine, keeping the product free of drug regulation by FDA. While Nicofi also is outside the agency’s current tobacco product authority, the firm is prepared for FDA oversight.